Last reviewed · How we verify
Part A
Part A is a Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved. Also known as: KETAMINE GROUP, Rituximab, Doxil, pegylated liposomal doxorubicin.
Part A, marketed by GlaxoSmithKline, holds a significant position in its therapeutic area with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Part A |
|---|---|
| Also known as | KETAMINE GROUP, Rituximab, Doxil, pegylated liposomal doxorubicin, cyclophosphamide |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (PHASE1, PHASE2)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor (PHASE1, PHASE2)
- NCI COVID-19 in Cancer Patients, NCCAPS Study
- Modified Tumor-free Techniques Operation to Cervical Cancer (NA)
- Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers (PHASE1)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Part A CI brief — competitive landscape report
- Part A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Part A
What is Part A?
Who makes Part A?
Is Part A also known as anything else?
What development phase is Part A in?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
- Also known as: KETAMINE GROUP, Rituximab, Doxil, pegylated liposomal doxorubicin, cyclophosphamide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing